Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar Disorder, Manic Clear all
Completed Phase 4 Interventional

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

NCT00094549
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, divalproex sodium, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Costa Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Jun 10, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lu AA39959, Placebo, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Mifepristone for Bipolar Depression

NCT00043654
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Mifepristone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Emotion Regulation Group Therapy for Bipolar Disorder

NCT01207505
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Enhancing Emotion Regulation
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Antidepressant Therapy in Treating Bipolar Type II Major Depression

NCT00602537
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Not applicable Interventional

A Study of Spoken Language in Mania

NCT05956340
View directory record Official record
Conditions
Manic Episode, Bipolar I Disorder
Interventions
Research interview
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional

Open Label Trial of Acamprosate in Bipolar Alcoholics

NCT00330486
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

NCT00571688
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperdal (risperidone) Consta, Treatment as usual
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

NCT00050206
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

Aripiprazole in Patients With Acute Mania

NCT00095511
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

NCT01805440
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Manic Depression
Interventions
Uridine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jun 10, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional

BHV-7000 Open-Label Extension Bipolar Mania Study

NCT06423794
View directory record Official record
Conditions
Bipolar Disorder
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

NCT00139594
View directory record Official record
Conditions
Bipolar Disorder
Interventions
licarbazepine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
La Palma, California • Kansas City, Kansas • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania

NCT03383874
View directory record Official record
Conditions
Mania (Neurotic)
Interventions
Probio-Tec BG-VCap-6.5, Placebo
Combination Product · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Little Rock, Arkansas • Cerritos, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Results available

Research Study of Bipolar Mood Symptoms and Cognitive Problems

NCT00428298
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

NCT00812058
View directory record Official record
Conditions
Bipolar I Depression
Interventions
RG2417, Placebo
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2011 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

NCT00294255
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jun 10, 2026, 5:27 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy Study of Lithium in Bipolar Disorder

NCT00422331
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
Lithium Carbonate Capsule
Drug
Lead sponsor
JDS Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2007 · Synced Jun 10, 2026, 5:27 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 2 Interventional

Clozapine for Treatment-Resistant Mania

NCT00029458
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Quetiapine & Placebo, Lithium and Placebo, Healthy Controls
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

The Young Adult and Pediatric Bipolar Study

NCT00350857
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Extended-Release Carbamazepine
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
26
States / cities
Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Jun 10, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539
View directory record Official record
Conditions
Schizophrenia
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jun 10, 2026, 5:27 AM EDT